MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers

BET inhibitors exhibit broad activity in cancer models, making predictive biomarkers challenging to define. Here we investigate the biomarkers of activity of the clinical BET inhibitor GSK525762 (I-BET; I-BET762) across cancer cell lines and demonstrate that KRAS mutations are novel resistance bioma...

Descripción completa

Detalles Bibliográficos
Autores principales: Wyce, Anastasia, Matteo, Jeanne J., Foley, Shawn W., Felitsky, Daniel J., Rajapurkar, Satyajit R., Zhang, Xi-Ping, Musso, Melissa C., Korenchuk, Susan, Karpinich, Natalie O., Keenan, Kathryn M., Stern, Melissa, Mathew, Lijoy K., McHugh, Charles F., McCabe, Michael T., Tummino, Peter J., Kruger, Ryan G., Carpenter, Christopher, Barbash, Olena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908790/
https://www.ncbi.nlm.nih.gov/pubmed/29674704
http://dx.doi.org/10.1038/s41389-018-0043-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908790/
https://www.ncbi.nlm.nih.gov/pubmed/29674704
http://dx.doi.org/10.1038/s41389-018-0043-9

Ejemplares similares